Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2017

01-07-2017 | Original Article

MALDI-ToF short incubation identification from blood cultures is associated with reduced length of hospitalization and a decrease in bacteremia associated mortality

Authors: J. A. Delport, A. Strikwerda, A. Armstrong, D. Schaus, M. John

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2017

Login to get access

Abstract

The purpose of this study was to assess the impact of MALDI-ToF identification and rapid short incubation MALDI-Tof identification protocol on patient care compared to conventional identification. By using a retrospective review we assessed the impact of a rapid Bruker MALDI-Tof identification protocol. Overall there was a 16.76-hour reduction in time to identification of the pathogen after the introduction of MALDI-TOF identification in 2013 (P<0.0001) and a further 15-hour reduction (P<9.37 E-05) after implementation of the short incubation MALDI-TOF identification protocol in 2014. Patients received appropriate therapy 20.25 hours earlier (P<0.002) in 2014 compared to the conventional identification group in 2012. Overall length in the patients needing optimization of antibiotic treatment was reduced by 6.87 days (P<0.042). In 2014 outcomes between the patients needing a change in their antibiotic compared to the patients where the empirical therapy was considered to be optimal were similar with respective difference in length of stay being reduced from 4.72 days (P<0.031) to 1.77 days (P<0.71) and an associated reduction in the absolute mortality risk of 3.79%. The all-cause mortality rate was twice as high in the group pre-implementation of the short incubation MALDI-TOF identification with an associated survival benefit in this patient population when 26 patients were treated. Rapid short incubation MALDI-ToF identification of bacterial pathogens in blood cultures is associated with a reduction in length of stay and mortality risk.
Literature
1.
go back to reference Mandell LA, Wunderink RG, Anzueto A et al (2009) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–72 Mandell LA, Wunderink RG, Anzueto A et al (2009) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–72
2.
go back to reference American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416CrossRef American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416CrossRef
3.
go back to reference Bodmann KF (2005) Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 51:227–233CrossRefPubMed Bodmann KF (2005) Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 51:227–233CrossRefPubMed
4.
go back to reference Shlaes DM, Gerding DN, John JF Jr et al (1997) Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25:584–599CrossRefPubMed Shlaes DM, Gerding DN, John JF Jr et al (1997) Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25:584–599CrossRefPubMed
5.
go back to reference Dellit TH, Owens RC, McGowan JE Jr et al (2007) Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed Dellit TH, Owens RC, McGowan JE Jr et al (2007) Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed
6.
go back to reference Verroken A, Defourny L, Lechgar L, Magnette A, Delmée M, Glupczynski Y (2015) Reducing time to identification of positive blood cultures with MALDI-TOF MS analysis after a 5-h subculture. Eur J Clin Microbiol Infect Dis 34:405–413CrossRefPubMed Verroken A, Defourny L, Lechgar L, Magnette A, Delmée M, Glupczynski Y (2015) Reducing time to identification of positive blood cultures with MALDI-TOF MS analysis after a 5-h subculture. Eur J Clin Microbiol Infect Dis 34:405–413CrossRefPubMed
7.
go back to reference Zabbe JB, Zanardo L, Mégraud F, Bessède E (2015) MALDI-TOF mass spectrometry for early identification of bacteria grown in blood culture bottles. J Microbiol Methods 115:45–46CrossRefPubMed Zabbe JB, Zanardo L, Mégraud F, Bessède E (2015) MALDI-TOF mass spectrometry for early identification of bacteria grown in blood culture bottles. J Microbiol Methods 115:45–46CrossRefPubMed
8.
go back to reference Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637CrossRefPubMed Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637CrossRefPubMed
9.
go back to reference Bryan CS, Reynolds KL, Brenner ER (1983) Analysis of 1,186 episodes of gram-negative bacteremia in non- university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 5:629–638CrossRefPubMed Bryan CS, Reynolds KL, Brenner ER (1983) Analysis of 1,186 episodes of gram-negative bacteremia in non- university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 5:629–638CrossRefPubMed
10.
go back to reference Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732–736CrossRefPubMed Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338:732–736CrossRefPubMed
11.
go back to reference Fraser A, Paul M, Almanasreh N et al (2006) Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119:970–976CrossRefPubMed Fraser A, Paul M, Almanasreh N et al (2006) Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 119:970–976CrossRefPubMed
12.
go back to reference Odetola FO, Gebremariam A, Freed GL (2007) Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 119:487–494CrossRefPubMed Odetola FO, Gebremariam A, Freed GL (2007) Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 119:487–494CrossRefPubMed
13.
go back to reference Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377CrossRefPubMed Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377CrossRefPubMed
14.
go back to reference Perez K, Randall J, Olsen RJ et al (2013) Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 137:1247–1254CrossRefPubMed Perez K, Randall J, Olsen RJ et al (2013) Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 137:1247–1254CrossRefPubMed
15.
go back to reference Kohlmann R, Hoffmann A, Geisb G, Gatermann G (2015) MALDI-TOF mass spectrometry following short incubation on a solid medium is a valuable tool for rapid pathogen identification from positive blood cultures. Int J Med Microbiol 305:469–479CrossRefPubMed Kohlmann R, Hoffmann A, Geisb G, Gatermann G (2015) MALDI-TOF mass spectrometry following short incubation on a solid medium is a valuable tool for rapid pathogen identification from positive blood cultures. Int J Med Microbiol 305:469–479CrossRefPubMed
16.
go back to reference Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474 Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474 
Metadata
Title
MALDI-ToF short incubation identification from blood cultures is associated with reduced length of hospitalization and a decrease in bacteremia associated mortality
Authors
J. A. Delport
A. Strikwerda
A. Armstrong
D. Schaus
M. John
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-2906-y

Other articles of this Issue 7/2017

European Journal of Clinical Microbiology & Infectious Diseases 7/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.